Immunotherapy of prostate cancer: Facts and hopes

Clinical Cancer Research

Volumn 23, Issue 22, 2017, Pages 6764-6770

  Bilusic, Marijo ^a   Madan, Ravi A ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGLATIMAGENE BESADENOVEC; BIOLOGICAL MARKER; CANCER VACCINE; CHECKPOINT KINASE INHIBITOR; DENDRITIC CELL VACCINE; DOCETAXEL; ENZALUTAMIDE; IMMUNOMODULATING AGENT; IPILIMUMAB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; IMMUNOLOGIC FACTOR;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CELL THERAPY; COMBINATION CHEMOTHERAPY; DISEASE ERADICATION; DRUG DOSE INTENSIFICATION; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; DRUG EFFECT; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROSTATE TUMOR;

CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS;

EID: 85034833547     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0019     Document Type: Review

References (54)

1. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580–93.
2. Drake CG, Jaffee E, Pardoll DM, De Marzo AM, Platz EA, Sutcliffe S, et al. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90: 51–81.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–69.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–22.
5. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907–17.
6. Drake CG. The potential role of antigen spread in immunotherapy for prostate cancer. Clin Adv Hematol Oncol 2014;12:332–4.
7. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer 2016;4:92.
8. Mahoney KM, Atkins MB, Gajewski TF. Prognostic and predictive markers for the new immunotherapies. Oncology 2014;28:39–48.
9. Gajewski TF. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol 2015;42: 663–71.
10. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214–8.
11. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174–9.
12. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017; 35:40–7.
13. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184–043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700–12.
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
15. Hansen A, Massard C, Ott P, Haas N, Ejadi S, Wallmark J, et al. Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study. Ann Oncol 2016;27:725PD.
16. Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 2015;18:325–32.
17. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 2014;5:4988.
18. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001;61:4112–21.
19. Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2014;2:133–41.
20. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099–105.
21. Kantoff PW, Gulley JL, Pico-Navarro C, Podrazil M, Horvath R, Becht E, et al. Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer. J Clin Oncol 2017;35:124–5.
22. Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/ PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015;6:18192–205.
23. Rojas-Martinez A, Manzanera AG, Sukin SW, Esteban-Maria J, Gonzalez-Guerrero JF, Gomez-Guerra L, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther 2013;20:642–9.
24. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014;257:56–71.
25. Slovin SF, Wang X, Borquez-Ojeda O, Stefanski J, Olszewska M, Taylor C, et al. Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CARþ T cells. J Clin Oncol 2012;30:abstr TPS4700-TPS.
26. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016;14:73.
27. O'Sullivan Coyne G, Madan RA, Gulley JL, Sutherland JS, Goldberg GL, Hammett MV, et al. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol 2014;32:986–8.
28. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741–53.
29. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239–49.
30. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565–70.
31. Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, et al. Antiandrogen, vaccine and combination therapy in patients with nonme-tastatic hormone refractory prostate cancer. J Urol 2005;174:539–46.
32. Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, et al. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 2013;19:6205–18.
33. Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 2015;6:234–42.
34. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810–7.
35. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013;133:624–36.
36. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16: 4583–94.
37. Finkelstein SE, Salenius S, Mantz CA, Shore ND, Fernandez EB, Shulman J, et al. Combining immunotherapy and radiation for prostate cancer. Clin Genitourin Cancer 2015;13:1–9.
38. Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, et al. Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: a randomized Phase 2 trial. Oncotarget 2016;7:69014–23.
39. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–23.
40. Malamas AS, Gameiro SR, Knudson KM, Hodge JW. Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreti-culin-mediated immunogenic modulation. Oncotarget 2016;7:86937–47.
41. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443–53.
42. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res 2015;3:1257–68.
43. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373:1697–708.
44. Karzai F, Madan RA, Owens H, Hankin A, Couvillon A, Houston N, et al. A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2017;35:abstr 162.
45. Schiewer MJ, Knudsen KE. Transcriptional roles of PARP1 in cancer. Mol Cancer Res 2014;12:1069–80.
46. Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother 2010;59:397–408.
47. Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014;74:4042–52.
48. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother 2015;38:1–11.
49. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014;106.
50. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39: 98–106.
51. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:509–17.
52. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:501–8.
53. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:501–8.
54. McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012;61:1137–47.